down arrow

OptiNose, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US68404V1008
USD
9.60
0.00 (0.00%)

May 22

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

4.8212.15
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

7.46%

Held by 35 FIIs

DII

57.81%

Held by 22 DIIs

Promoter

13.89%

How big is OptiNose, Inc.?

22-Jun-2025

As of May 22, OptiNose, Inc. has a market capitalization of 96.53 million, with net sales of 81.86 million and a net profit of -29.97 million over the last four quarters. The balance sheet as of December 2024 shows shareholder's funds of -40.36 million and total assets of 128.78 million.

As of May 22, OptiNose, Inc. has a market capitalization of 96.53 million, categorizing it as a Micro Cap company.<BR><BR>As of the latest four quarters, the company reported net sales of 81.86 million and a net profit of -29.97 million.<BR><BR>As of December 2024, the balance sheet shows shareholder's funds of -40.36 million and total assets of 128.78 million.

Read More

What does OptiNose, Inc. do?

22-Jun-2025

OptiNose, Inc. is a pharmaceutical company specializing in products for ENT and allergy specialists, with a market cap of $96.53 million. As of March 2025, it reported net sales of $19 million and a net loss of $22 million.

Overview: <BR>OptiNose, Inc. is a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists, operating within the micro-cap market.<BR><BR>Financial Snapshot: <BR>Net Sales: 19 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -22 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 96.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Dividend Yield: 93.75% <BR>Debt Equity: -0.90 <BR>Return on Equity: 47.92% <BR>Price to Book: -1.57<BR><BR>Contact Details: <BR>Address: 1020 Stony Hill Rd Ste 300, YARDLEY PA: 19067-5539 <BR>Tel: 1 267 3643500 <BR>Website: https://www.optinose.com/

Read More

Should I buy, sell or hold OptiNose, Inc.?

22-Jun-2025

Who are in the management team of OptiNose, Inc.?

22-Jun-2025

As of March 2022, the management team of OptiNose, Inc. includes Mr. Joseph Scodari (Independent Chairman), Mr. Peter Miller (CEO and Director), Mr. Tomas Heyman, Ms. Catherine Owen, Mr. Wilhelmus Groenhuysen, and Ms. Sandra Helton (all Directors). They oversee the company's operations and strategic direction.

As of March 2022, the management team of OptiNose, Inc. includes the following individuals:<BR><BR>- Mr. Joseph Scodari, who serves as the Independent Chairman of the Board.<BR>- Mr. Peter Miller, who is the Chief Executive Officer and a Director.<BR>- Mr. Tomas Heyman, who is a Director.<BR>- Ms. Catherine Owen, who is also a Director.<BR>- Mr. Wilhelmus Groenhuysen, who serves as an Independent Director.<BR>- Ms. Sandra Helton, who is an Independent Director. <BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Mar 25

  • INVENTORY TURNOVER RATIO(HY) Lowest at 0.74%
  • EPS(Q) Lowest at USD -1.92 MM
2

Risky - Not traded in last 10 days

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 97 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

93.75%

stock-summary
Debt Equity

-0.90

stock-summary
Return on Equity

47.92%

stock-summary
Price to Book

-1.57

Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Mar 2025)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
66.38%
0%
66.38%
6 Months
33.33%
0%
33.33%
1 Year
-44.83%
0%
-44.83%
2 Years
627.27%
0%
627.27%
3 Years
-67.01%
0%
-67.01%
4 Years
-79.94%
0%
-79.94%
5 Years
-86.06%
0%
-86.06%

OptiNose, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.07%
EBIT Growth (5y)
12.88%
EBIT to Interest (avg)
-2.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
1.26
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.63%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.57
EV to EBIT
-9.60
EV to EBITDA
-9.77
EV to Capital Employed
-25.70
EV to Sales
1.86
PEG Ratio
NA
Dividend Yield
93.75%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 24 Schemes (20.84%)

Foreign Institutions

Held by 35 Foreign Institutions (7.46%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 24.16% vs 26.27% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -58.87% vs 25.00% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.50",
          "val2": "14.90",
          "chgp": "24.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.50",
          "val2": "-8.00",
          "chgp": "6.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.90",
          "val2": "5.00",
          "chgp": "-2.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.60",
          "val2": "-1.30",
          "chgp": "-715.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.40",
          "val2": "-14.10",
          "chgp": "-58.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-410.00%",
          "val2": "-542.70%",
          "chgp": "13.27%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.14% vs -6.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 39.44% vs 52.54% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "78.20",
          "val2": "71.00",
          "chgp": "10.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.00",
          "val2": "-22.30",
          "chgp": "28.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "20.10",
          "val2": "19.50",
          "chgp": "3.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "4.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.50",
          "val2": "-35.50",
          "chgp": "39.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-208.60%",
          "val2": "-320.50%",
          "chgp": "11.19%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
18.50
14.90
24.16%
Operating Profit (PBDIT) excl Other Income
-7.50
-8.00
6.25%
Interest
4.90
5.00
-2.00%
Exceptional Items
-10.60
-1.30
-715.38%
Consolidate Net Profit
-22.40
-14.10
-58.87%
Operating Profit Margin (Excl OI)
-410.00%
-542.70%
13.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2025 is 24.16% vs 26.27% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -58.87% vs 25.00% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
78.20
71.00
10.14%
Operating Profit (PBDIT) excl Other Income
-16.00
-22.30
28.25%
Interest
20.10
19.50
3.08%
Exceptional Items
0.00
4.30
-100.00%
Consolidate Net Profit
-21.50
-35.50
39.44%
Operating Profit Margin (Excl OI)
-208.60%
-320.50%
11.19%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 10.14% vs -6.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 39.44% vs 52.54% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About OptiNose, Inc. stock-summary
stock-summary
OptiNose, Inc.
Pharmaceuticals: Major
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.
Company Coordinates stock-summary
Company Details
1020 Stony Hill Rd Ste 300 , YARDLEY PA : 19067-5539
stock-summary
Tel: 1 267 3643500
stock-summary
https://www.optinose.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."